封面
市場調查報告書
商品編碼
1481417

全球止血產品市場規模、佔有率、成長分析、依產品(局部止血產品、不熔止血產品)、依應用(創傷、手術)、依最終用戶(醫院、診所)-2024-2031 年產業預測

Global Hemostasis Products Market Size, Share, Growth Analysis, By Product(Topical Hemostasis Products, Infusible Hemostasis Products), By Application(Trauma, Surgery), By End-user(Hospitals, Clinics) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年全球止血產品市場規模為16.0億美元,預計將從2023年的16.9億美元成長到2031年的25.9億美元,在預測期間(2024-2031年)複合年成長率為5.5%。

由於人們意識的提高和醫療技術的進步,止血產品市場在全球範圍內穩步擴大。這些藥物對於治療各種出血問題以及手術和創傷後止血至關重要。人口老化、慢性病增加和手術增加推動了止血產品市場的發展。發展中國家醫療保健設施日益普及也促進了產業擴張。此外,持續的研發努力促使新型止血產品的推出,增強了其有效性和安全性。然而,這些產品昂貴的成本和監管障礙可能會阻礙該行業的擴張。儘管存在這些障礙,隨著醫療保健標準和技術的進步,全球止血產品市場預計將成長。

目錄

執行摘要

  • 市場概況
  • 命運之輪

研究方法論

  • 資訊採購
  • 二手和主要資料來源
  • 市場規模估計
  • 市場假設與限制

母公司市場分析

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題

主要市場洞察

  • 技術分析
  • 定價分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • 啟動分析
  • 原料分析
  • 創新矩陣
  • 管道產品分析
  • 總體經濟指標
  • 頂級投資分析
  • 成功的關鍵因素
  • 競爭程度

市場動態與展望

  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題
  • 監管環境
  • 波特分析
  • 對未來顛覆的特別見解

全球止血產品市場(依產品)

  • 市場概況
  • 局部止血產品
  • 不輸止血產品
  • 先進的止血產品

全球止血產品市場(依應用)

  • 市場概況
  • 創傷
  • 手術
  • 血友病
  • 心肌梗塞

全球止血產品市場(依最終用戶)

  • 市場概況
  • 醫院
  • 診所
  • 其他

全球止血產品市場規模(依地區)

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 拉丁美洲其他地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • MEA 的其餘部分

競爭格局

  • 前 5 名企業比較
  • 2023 年關鍵參與者的市場定位
  • 主要市場參與者所採取的策略
  • 最佳制勝策略
  • 近期市集活動
  • 主要公司市佔率 (%), 2023

主要公司簡介

  • Johnson & Johnson (US)
  • Pfizer (US)
  • Baxter International (US)
  • Medtronic (US)
  • B. Braun Melsungen AG (Germany)
  • Becton, Dickinson, and Company (BD) (US)
  • Tricol Biomedical (US)
  • Hemostasis LLC (US)
  • CuraMedical BV (Netherlands)
  • Teleflex Incorporated (US)
  • CryoLife, Inc. (US)
  • Ethicon, Inc. (US)
  • Grifols, SA (Spain)
  • Terumo Corporation (Japan)
  • Integra LifeSciences Holdings Corporation (US)
  • HemCon Medical Technologies, Inc. (US)
  • Zimmer Biomet Holdings, Inc. (US)
  • Haemonetics Corporation (US)
  • CSL Behring LLC (Australia)
  • Olympus Corporation (Japan)
簡介目錄
Product Code: SQMIG35A2702

Global Hemostasis Products Market size was valued at USD 1.60 billion in 2022 and is poised to grow from USD 1.69 billion in 2023 to USD 2.59 billion by 2031, growing at a CAGR of 5.5% during the forecast period (2024-2031).

The market for hemostasis products is expanding steadily on a global scale as a result of rising awareness and improvements in medical technology. These medicines are essential for managing a variety of bleeding problems as well as for stopping bleeding after surgery and trauma cases. The market for hemostasis products is being driven by an aging population, an increase in chronic diseases, and an increase in surgeries. The growing accessibility of healthcare facilities in developing nations is also fostering industry expansion. In addition, continuous R&D endeavors are resulting in the launch of novel hemostasis products, augmenting their effectiveness and safety. The expensive cost of these items and regulatory obstacles, however, may prevent the industry from expanding. Notwithstanding these obstacles, the market for hemostasis products worldwide is expected to grow as healthcare standards and technologies advance.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostasis Products Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemostasis Products Market Segmental Analysis

The global hemostasis products market is segmented on the basis of product, application, end-user, and region. Based on product, the market is segmented as Topical Hemostasis Product, Infusible Hemostasis Products, and Advanced Hemostasis Products. On the basis of application, the market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction. Based on the end-user, it is segregated into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Hemostasis Products Market

The treatment of bleeding problems and surgical operations are being significantly improved by innovations like the development of more environmentally friendly and safe hemostasis products, in addition to hemostatic agents and devices. These upgrades enhance patient outcomes and put pressure on a rise in the market.

Restraints in the Global Hemostasis Products Market

One of the most notable commercial constraints is the high price of hemostasis products. These products may be expensive, which limits their availability to patients in some areas and healthcare facilities with limited funding. The cost factor may prevent the widespread use of better hemostasis solutions, limiting their market penetration and possibly impairing patient care.

Market Trends of the Global Hemostasis Products Market

Both patients and healthcare organizations are looking for less intrusive ways to treat bleeding problems and surgical procedures. This movement makes use of the advancements in progressive hemostasis products and methods, which lessen tissue damage, speed up repair, and improve average patient outcomes. Due to its potential to improve patient comfort and reduce hospital stays, minimally invasive hemostasis techniques are gaining popularity. This trend is in line with the healthcare industry's emphasis on value-based treatment.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Hemostasis Products Market by Product

  • Market Overview
  • Topical Hemostasis Products
  • Infusible Hemostasis Products
  • Advanced Hemostasis Products

Global Hemostasis Products Market by Application

  • Market Overview
  • Trauma
  • Surgery
  • Hemophilia
  • Myocardial Infarction

Global Hemostasis Products Market by End-user

  • Market Overview
  • Hospitals
  • Clinics
  • and Others

Global Hemostasis Products Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Johnson & Johnson (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtronic (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • B. Braun Melsungen AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Becton, Dickinson, and Company (BD) (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Tricol Biomedical (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hemostasis LLC (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CuraMedical BV (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teleflex Incorporated (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CryoLife, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ethicon, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Grifols, S.A. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Terumo Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Integra LifeSciences Holdings Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • HemCon Medical Technologies, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zimmer Biomet Holdings, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Haemonetics Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CSL Behring LLC (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Olympus Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments